TScan Therapeutics, Inc. TCRX 深 滬
已收盤 02-06 16:00:00 美东时间
1.03
+0.120
+13.14%
華盛通- 最 高1.04
- 今 開0.9382
- 成交量 108.48万股
- 最 低 0.895
- 昨 收 0.9104
- 總市值 5845.04万
- 52周最高 2.57
- 市盈率 靜 --
- 換手率 1.91%
- 52周最低 0.8824
- 委 比 -61.57%
- 總股本 5674.80万
- 歷史最高 14.71
- 量 比 2.36
- 振 幅 15.93%
- 歷史最低 0.8824
- 每 手 1
- 風險率 0.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 19, 2025 /PRNewswire/ -- Equity Insider News Commentary – The oncology sector's pivot toward platform-based precision therapies has...
2025-12-19 20:55
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia ...
2025-12-05 01:20
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Andres Y. Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $10 to $7.
2025-11-13 20:53
TScan Therapeutics Q3 EPS $(0.28) Beats $(0.30) Estimate, Sales $2.511M Beat $1.980M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 5.41 percent. This is a 12 percent decrease over losses of $(0.25) per share from
2025-11-12 20:13
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
BTIG Downgrades TScan Therapeutics to Neutral
BTIG analyst Justin Zelin downgrades TScan Therapeutics (NASDAQ:TCRX) from Buy to Neutral.
2025-11-04 19:23
TScan Therapeutics shares are trading lower. The company announced regulatory and clinical program updates, implementation of a workforce reduction of approximately 30%, and extension of its cash runway into the second half of 2027.
TScan Therapeutics shares are trading lower. The company announced regulatory a...
2025-11-03 22:22
TScan Therapeutics To Present New Research On T Cell Therapies At ACR Convergence 2025 In Chicago
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today
2025-09-17 19:03
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
<p>TScan Therapeutics announced the acceptance of two abstracts for presentation at the ACR Convergence 2025, highlighting novel T cell targets in autoimmune disorders like Ankylosing Spondylitis using their TargetScan technology. The findings aim to advance therapies for these conditions.</p>
2025-09-17 11:00
